Fred Hutch Cancer Center researchers are seeking better ways to prevent, detect and treat bladder cancer. We are also working to better understand the factors that affect each person’s risk for this cancer. Our scientists are also developing new methods to gauge how well a tumor will respond to treatment.
Physician-researchers at Fred Hutch are running many clinical trials of new drugs and drug combinations to treat different types of bladder cancer. These experimental therapies are part of a trend toward precision cancer care. The idea behind precision care is to target a patient’s tumor based on its molecular profile. We continue to hunt for more potential targets on bladder cancer cells that could lead to even more treatment options.
Bladder Cancer Clinical Trials
Fred Hutch typically has over 750 active cancer clinical trials enrolling participants.
Clinical trials may allow some patients access to a promising new treatment, and help physicians and researchers learn more about a disease.
Researchers ID Potential New Drug Target in Bladder Cancer
Andrew Hsieh, MD, and Sujata Jana, PhD, former postdoctoral research fellow and now staff scientist, found that blocking protein synthesis slows bladder tumor development and progression in lab studies.
Our Bladder Cancer Researchers and Faculty
Our scientists and providers work together to prevent, diagnose and treat bladder cancer as well as other cancers and diseases. The lab research and clinical research they do are essential parts of the scientific process that leads to new treatments and better care. Many of our bladder cancer providers also do research in addition to seeing patients. Clinical trials can also be a way for patients to get early access to new leading-edge therapies. Our research teams are running many clinical studies for people with bladder cancer.
